Cardio Diagnostics Uses Epigenetics to Uncover Hidden Heart Disease Risks

When most people consider their risk for heart disease, they think about family history—whether a parent or grandparent had a heart attack. It is an understandable assumption, and genetics does play a role. However, a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest is written in epigenetics, a field examining how genes are switched on or off without changing the underlying DNA code.

Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company based on epigenetics-based cardiovascular testing, has placed this science at the core of its diagnostic platform. By analyzing an individual’s epigenetics, the company provides invaluable insight into how lifestyle, behavior, and environment affect heart health. According to the company’s CEO, epigenetics does more than pinpoint a problem; it also offers a pathway to solutions.

Understanding epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often, and how loudly. Epigenetics essentially controls this reading process, influenced by factors such as diet, exercise, stress, and exposure to toxins.

For the state of Texas, where heart disease remains a leading cause of death, this approach could have significant implications. By identifying hidden risks that traditional genetic tests might miss, Cardio Diagnostics’ platform empowers individuals and healthcare providers to take proactive steps. For businesses, healthier employees mean reduced healthcare costs and improved productivity. The technology also aligns with Texas’ growing reputation as a hub for innovative medical and biotech companies, potentially attracting investment and talent.

Cardio Diagnostics’ work highlights a shift in cardiovascular medicine: moving from a reactive to a preventive model. As the science of epigenetics evolves, it may become a standard tool in heart health assessment. For more information, readers can explore the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer and follow the latest updates on CDIO in the company’s newsroom at https://ibn.fm/CDIO.

This article contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause actual results to differ materially. Undue reliance should not be placed on them in making an investment decision.